117574-75-1

Upstream product

• 117574-74-0 (2,5-dimethoxy-3,4,6-trimethylphenyl)methanol 
• 50-00-0 formaldehyd 
• 4537-09-1 1,4-dimethoxy-2,3,5-trimethyl-benzene 
• 103808-42-0 2,5-dimethoxy-3,4,6-trimethylbenzaldehyde 

Downstream Products

• 144707-05-1 1,4-dimethoxy-2-methoxymethyl-3,5,6-trimethylbenzene 
• 174337-36-1 9-(2,5-dimethoxy-3,4,6-trimethylbenzyl)-2,3,9,10a-tetrahydrobenzo [b]cyclopenta[e][1,4]diazepin-10(1H)-one 
• 117574-76-2 3-(2,5-dimethoxy-3,4,5-trimethylbenzyl)pyridine 
• 104157-20-2 1,2,4,5-tetrakis(bromomethyl)-3,6-dimethoxybenzene 
• 17228-90-9 bis(2,5-dimethoxy-3,4,6-trimethylphenyl)methane 
• 305347-58-4 1,8-bis(2,5-dimethoxy-3,4,6-trimethylphenyl)-octa-3,5-diyne 
• 305347-72-2 1,8-bis(2,4,5-dimethyl-3,6-dioxocyclohexa-1,4-dienyl)-octa-3,5-diyne 
• 133185-77-0 4-(2,5-dimethoxy-3,4,6-trimethylphenyl)-but-1-yne 

Relevant academic research and scientific papers

An ether-linked halogenated phenazine-quinone prodrug model for antibacterial applications

Antibiotic-resistant infections present significant challenges to patients. As a result, there is considerable need for new antibacterial therapies that eradicate pathogenic bacteria through non-conventional mechanisms. Our group has identified a series o

Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release

Histone deacetylase inhibitors (HDACi) target abnormal epigenetic states associated with a variety of pathologies, including cancer. Here, the development of a prodrug of the canonical broad-spectrum HDACi suberoylanilide hydroxamic acid (SAHA) is describ

Hydrindacene-based acetylenic macrocycles with horizontally and vertically ordered functionality arrays

The macrocyclization of 2,6-diethynyl hydrindacenes (1) with functional groups at mutually perpendicular positions results in the formation of novel macrocycles which, as a result of the hindered rotation of the hydrindacene units, possess directionally persistent peripheral functionalities. The two hydrindacene units in the dimer macrocycle (2) have been shown to interact electronically through their respective butadiyne moieties, whereas the trimer macrocycle (3) demonstrates a moderate degree of geometrical flexibility as a result of the five-membered hydrindacene rings. In addition, these trimer macrocycles contain a central cavity suitably sized for the inclusion of various solvent molecules. These new macrocycles can be further modified by introducing π-conjugated side groups, such as styryl and thienyl groups, as well as by attaching a variety of peripheral ester groups. Copyright

Quinone derivatives, their production and use.

Quinone derivatives represented by the general formula (wherein, R1 and R2, which are the same or different, refer to a hydrogen atom, methyl or methoxymethyl group, or R1 and R2 bind together to form-CH=CH-CH=CH-; R3 is a hydrogen atom or methyl group; R? is a nitrogen-containing heterocyclic group which may be substituted; R? is a hydrogen atom, methyl group, hydroxymethyl group which may be substituted, or a carboxyl group which may be (wherein, R' is a hydrogen atom or methyl group); n is an integer from 0 through 12, m is an integer from 0 through 3, and k is an integer from 0 through 7, providing that, when m is 2 or 3, Z and k are able to vary appropri-ately in the repeating unit shown in [ ] ), and the hydro-quinone derivatives thereof, are novel compounds, possess improvement effects of metabolism of poly unsaturated fatty acids, particularly two or more of inhibition of production of fatty acid peroxides, inhibition of production of metabo-lites in 5-lipoxygenase pathway, inhibition of thromboxane A? synthetase, thromboxane A? receptor antagonism and scavenging action of active oxygen species, and of use as drugs, such as antithrombotics, anti-vascular constriction agents, anti-asthma agent, antiallergic agents, therapeutics for psoriasis, agents for improvement in heart, brain and cardiovascular systems, therapeutics for nephritis, active oxygen-eliminating agents, anticancer agents, agents for improvement of control of arachidonate cascade products, etc.

Certain benzoquinones, naphthoquinones, corresponding hydroquinones which exhibit thromboxane A2 synthetase inhibition or receptor antagonism and the like

Quinone derivatives represented by the general formula STR1 (wherein, R1 and R2, the same or different, refer to a hydrogen atom, methyl or methoxymethyl group, or R1 and R2 bind together to form --CH=CH--CH=CH--; R3 is a hydrogen atom or methyl group; R4 is a nitrogen-containing heterocyclic group which may be substituted; R5 is a hydrogen atom, methyl group, hydroxymethyl group which may be substituted, or a carboxyl group which may be esterified or amidated; Z is STR2 (wherein, R' is hydrogen atom or methyl group); n is an integer from 0 through 12, m is an integer from 0 through 3, and k is an integer from 0 through 7, providing that, when m is 2 or 3, Z and k are able to vary appropriately in the repeating unit shown in [ ]), and the hydroquinone derivatives thereof, are novel compounds, possess improvement effects of metabolism of polyunsaturated fatty acids, particularly two or more of inhibition of production of fatty acid peroxides, inhibition of production of metabolites in 5-lipoxygenase pathway, inhibition of thromboxane A2 synthetase, thromboxane A2 receptor antagonism and scavenging action of active oxygen species, and of use as drugs, such as antithrombotics, anti-vascular constriction agents, anti-asthma agent, antiallergic agents, therapeutics for psoriasis, agents for improvement in heart, brain and cardiovascular systems, therapeutics for nephritis, active oxygen-eliminating agents, anticancer agents, agents for improvement of control of arachidonate cascade products, etc.